What Is Selank?
Selank is a synthetic peptide made from seven amino acids. It was developed in Russia from tuftsin, a natural four-amino-acid fragment involved in immune signalling, and has been studied mainly for possible effects on anxiety and the nervous system.
Some human research has compared Selank with established anti-anxiety medicines. However, the clinical evidence is small, comes largely from connected Russian research groups and does not meet the standard normally expected for approval in the United States or European Union.
What is Selank made from?
Selank has the sequence threonine, lysine, proline, arginine, proline, glycine and proline. Its abbreviated sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, or TKPRPGP.
An amino acid is a small building block used to make peptides and proteins. A chain of seven amino acids is called a heptapeptide. The first four amino acids of Selank reproduce the sequence of tuftsin. The final proline-glycine-proline section was added to change the stability and biological behaviour of the molecule.
Tuftsin is released from immunoglobulin G, normally shortened to IgG. IgG is a type of antibody, a protein used by the immune system to recognise and respond to possible threats. Calling Selank a tuftsin analogue means that it was designed from tuftsin's structure. It does not mean that Selank is an antibody or that every effect of tuftsin also applies to Selank.
Why was tuftsin extended by three amino acids?
Tuftsin is short and is readily broken down by peptidases, enzymes that cut peptide bonds. Adding proline-glycine-proline was intended to make the designed peptide more resistant to breakdown and to change how long its biological effects could last in experiments.
The three added amino acids are not an inactive tail. When a peptide is broken down, shorter fragments can sometimes have biological activity of their own. Researchers studying the tuftsin family have therefore compared Selank with tuftsin and with several possible fragments rather than assuming that the complete seven-amino-acid chain is the only active form.
This complicates mechanism claims. An experimental effect could involve Selank itself, one or more breakdown products, or a change in the breakdown of other natural peptides. A structural explanation can identify possibilities, but it cannot show which pathway produces a clinical effect in people.
The sequence also does not make Selank a natural human hormone. Its first four amino acids mirror a naturally occurring fragment, but the seven-amino-acid molecule was deliberately designed and is made synthetically for research or pharmaceutical production.
When was Selank first documented?
Selank was developed by researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences and the V.V. Zakusov Research Institute of Pharmacology. These are Russian public research institutes working in molecular biology and pharmacology.
The available record does not provide one clear date on which a finished Selank molecule was first created. Its development belongs to a wider Russian programme studying short regulatory peptides in the late twentieth century. By 2002, an English-indexed paper was describing Selank's effects in mice. A 2003 paper placed it within a family of tuftsin-derived compounds. The best-known clinical comparison with medazepam was published in 2008.
This timeline separates three different events that are sometimes merged online: the earlier discovery of tuftsin, the later design of Selank and the eventual publication of clinical findings. The first English-indexed papers are evidence that Selank was being studied by that time, but they do not prove the exact date of invention.
| Timeframe | What was documented |
|---|---|
| Late twentieth century | Russian researchers developed short tuftsin-related regulatory peptides |
| 2002 | An English-indexed animal paper reported behavioural and enzyme findings with Selank |
| 2003 | A paper described Selank within the wider tuftsin peptide family |
| 2008 | A 62-person clinical comparison with medazepam was published |
| 2010s | Laboratory studies examined gene activity, GABA-related signalling and interactions with diazepam |
How is Selank synthesised and manufactured?
Selank used in research is made chemically rather than extracted from human blood or immune tissue. A common method for short peptides is solid-phase peptide synthesis, usually shortened to SPPS.
In SPPS, the first protected amino acid is attached to small insoluble resin beads. A resin is a solid support that holds the growing peptide chain. The remaining amino acids are added in the required order. Temporary protecting groups cover parts of each amino acid that should not react during that step. Chemists remove one temporary group, join the next amino acid and repeat the cycle until the seven-amino-acid chain is complete.
The raw peptide building blocks correspond to Selank's sequence: protected forms of threonine, lysine, proline, arginine and glycine. Proline appears three times in the finished chain. Manufacturing also requires a solid resin, coupling chemicals that help form peptide bonds, protecting-group reagents and solvents suitable for peptide chemistry. These supporting materials help make the molecule but are not intended to remain in the purified peptide.
After chain assembly, the peptide is released from the resin and its remaining protecting groups are removed. The crude material contains the desired sequence alongside incomplete chains and chemical by-products. Preparative high-performance liquid chromatography, or HPLC, can separate these components. HPLC passes a mixture through a column so that different molecules leave at different times.
The final identity can be checked by mass spectrometry, which measures molecular mass, and analytical HPLC can estimate purity. Pharmaceutical manufacture would also require validated control of contaminants, residual solvents, microorganisms and batch consistency. A laboratory statement such as “research grade” does not by itself show that those pharmaceutical standards have been met.
This overview explains the manufacturing principle. It is not an operating protocol and does not provide quantities, timings, temperatures, equipment settings, sterile filling steps or instructions for preparing a product for use.
What does “anxiolytic” mean?
Selank is often described as anxiolytic. An anxiolytic is a medicine or research compound intended to reduce anxiety.
Anxiety can be a normal response to stress. An anxiety disorder is different: fear, worry or physical symptoms are persistent enough to cause distress or interfere with daily life. A biological effect in a mouse placed in an unfamiliar enclosure is not the same as relief of a diagnosed anxiety disorder in a person.
Selank has also been called a nootropic, meaning a substance claimed to improve memory, attention or other aspects of thinking. This label describes a proposed purpose, not proof of a benefit.
How might Selank work?
There is no settled human mechanism. A mechanism is the biological process through which a substance may produce an effect.
Several studies focus on gamma-aminobutyric acid, normally shortened to GABA. GABA is a neurotransmitter, a chemical that nerve cells use to communicate. It usually reduces the activity of the receiving nerve cell. Benzodiazepines, including diazepam and medazepam, strengthen signalling through one family of GABA receptors.
Researchers have reported that Selank changes the activity of some genes connected with GABA signalling in cell and animal models. A gene contains instructions that a cell can use to make a molecule. Gene expression describes how actively those instructions are being used. A change in gene expression does not show by itself that a person's anxiety or thinking has improved.
Other work has examined enkephalins. These are naturally produced peptides involved in pain, stress and emotion. A 2002 mouse study found that Selank slowed the breakdown of leucine-enkephalin in one strain of mice but not another. The difference between strains shows why a result from one animal model may not transfer reliably to humans.
Studies have also reported changes involving serotonin, dopamine and brain-derived neurotrophic factor, or BDNF. Serotonin and dopamine are neurotransmitters. BDNF is a protein involved in the survival and adaptation of nerve cells. None of these findings provides a complete explanation of Selank's effects in people.
What does the GABA research actually show?
Some laboratory findings describe Selank as a positive allosteric modulator of GABA-related signalling. An allosteric modulator attaches to a receptor at a site different from the main signalling molecule and changes how the receptor responds. This is not the same as saying that Selank is GABA or that it works exactly like a benzodiazepine.
One cell study exposed rat nerve-cell cultures to Selank or GABA and measured messenger RNA at several time points. Messenger RNA is the temporary copy of a gene's instructions used by a cell. The researchers found overlapping changes in some genes involved in neurotransmission. This suggested a possible connection with the GABA system, but the experiment did not measure anxiety, concentration or sleep in a person.
A separate rat study compared Selank, diazepam and the combination. It measured gene activity in brain tissue after the experiment. Diazepam is a benzodiazepine that has known clinical effects through GABA-A receptors. Changes in the combination group may help researchers study interactions, but they do not show that the combination is helpful or safe in people.
The concentrations used in a culture dish and the amount reaching rat brain tissue cannot be treated as human exposure. Cell membranes, metabolism, blood flow and the blood-brain barrier all affect what reaches a human brain. The blood-brain barrier is a tightly controlled boundary between the circulation and brain tissue.
These studies support a GABA-related hypothesis. They do not establish a settled receptor target, a clinical strength of effect or equivalence to a licensed anti-anxiety medicine.
What does the enkephalin research add?
Enkephalins are short peptides made by the body. They attach to opioid receptors and take part in pain, stress and emotional signalling. They are broken down quickly by several enzymes.
An experiment using human blood plasma found that Selank slowed the enzymatic breakdown of leucine-enkephalin in the test system. The concentration that produced half of the measured inhibition was about 15 micromolar. A micromolar is one millionth of a mole per litre and is a laboratory concentration, not a treatment level.
The later mouse work found that the result differed between mouse strains. A strain is a genetically defined line of laboratory animals. A biological effect appearing in one strain but not another suggests that inherited biology or baseline behaviour may influence the response.
Neither experiment shows that Selank raises enkephalin activity in the human brain after administration. Blood plasma outside the body is not the same environment as the central nervous system, and an enzyme effect does not establish relief from an anxiety disorder.
What did the main human anxiety study examine?
The main English-indexed clinical paper included 62 adults. Thirty had generalised anxiety disorder, a condition involving persistent and difficult-to-control worry. The remaining participants were described as having neurasthenia, an older diagnostic term associated with fatigue, irritability and weakness that is not used consistently in modern international practice.
Thirty participants received Selank and 32 received medazepam. Medazepam is a benzodiazepine anti-anxiety medicine. The researchers used established questionnaires, including the Hamilton Anxiety Rating Scale and the Zung Self-Rating Anxiety Scale, to measure symptoms before and during treatment.
The paper reported that both groups showed a similar reduction in anxiety. It also described Selank as having less sedating activity and some effect on fatigue. Sedation means reduced alertness or increased sleepiness.
The study administration level was 2.7 milligrams of Selank per day through the nose for 14 days. The medazepam comparison level was 15 milligrams per day. These figures describe that particular trial. They are not personal dosing or application instructions.
How reliable is that study?
The trial is relevant because it tested Selank in people with symptoms rather than only in cells or animals, and because it used an established medicine as a comparison. It does not settle the question. Orentra Labs explains this approach to weighing different kinds of evidence separately.
The sample was small. The PubMed abstract does not provide a complete account of randomisation, masking, withdrawals or adverse-event collection. Randomisation means assigning people to groups by chance. Masking means keeping participants or researchers unaware of the assigned treatment to reduce the effect of expectations. It is also unclear from the abstract whether the products could be made to appear identical.
The study lasted only two weeks. Anxiety disorders often require longer assessment, and a short trial cannot show whether a benefit lasts or whether uncommon or delayed harms occur. There is also little independent replication from research groups outside the network that developed Selank.
The most accurate conclusion is that the study offers an early human signal, not firm evidence that Selank is equivalent to an established treatment.
What did the comparison with phenazepam find?
A second comparative report published in 2014 included 60 people with phobic-anxiety or somatoform disorders. Phobic-anxiety disorders involve marked fear linked to particular situations or objects. Somatoform was an older diagnostic grouping for physical symptoms associated with psychological distress that were not fully explained by a medical condition.
The study compared Selank with phenazepam. Phenazepam is a benzodiazepine developed in the former Soviet Union. The abstract reported a pronounced reduction in anxiety, a mild effect on cognitive measures and better tolerability with Selank. It also stated that an anti-anxiety effect continued for one week after the final administration.
The indexed abstract does not state the group sizes, numerical changes, confidence intervals, randomisation method or masking procedure. A confidence interval gives a range of values compatible with the data and helps show the uncertainty around an estimate. Without these details, the size and reliability of the reported difference are difficult to judge.
The diagnoses also covered several categories rather than one clearly defined modern trial population. This matters because symptoms, expected course and response to a comparison medicine can differ across disorders.
The paper is useful as another human observation, but it is not an independent international replication. It came from the same broader Russian clinical and research setting as much of the Selank literature. Its findings should therefore be reported, but not treated as confirmation from an unrelated development programme.
Has Selank been studied with other anxiety medicines?
A 2015 report examined Selank alongside phenazepam, another benzodiazepine. Thirty participants received phenazepam alone and 40 received phenazepam with Selank. The publication described fewer unwanted effects associated with phenazepam when the peptide was included, including less sedation and fewer attention or memory complaints.
The comparison does not show that Selank prevents benzodiazepine side effects in routine care. The available English abstract does not provide the numerical adverse-event results, masking procedure or enough detail to judge whether expectations and treatment differences influenced reporting. It also tested an add-on strategy rather than Selank alone.
An animal study also examined Selank with diazepam. It found that the combination changed the expression of several genes in rat brain tissue. That is a molecular result from animals, not evidence that people should combine the substances.
These publications do not establish a safe or effective combination strategy. This guide provides no stacking or treatment advice.
What is the complete human evidence picture?
The indexed human literature is larger than one trial, but it remains a small collection rather than a modern international development programme.
| Report | Participants and comparison | What it adds | Main limit |
|---|---|---|---|
| 2008 medazepam comparison | 62 adults; 30 received Selank and 32 medazepam | Direct symptom comparison with an established benzodiazepine over 14 days | Small, brief and incompletely described in the English abstract |
| 2008 immune report | People with anxiety-asthenic disorders plus blood-cell experiments | Exploratory cytokine and IL-6 measurements | Does not establish an immune treatment or clinical mechanism |
| 2014 phenazepam comparison | 60 adults with several anxiety or somatoform diagnoses | Second active-medicine comparison and a report of a one-week continuing effect | Group allocation, numerical effect sizes and masking are not reported in the indexed abstract |
| 2015 phenazepam add-on study | 70 adults; 30 received phenazepam and 40 received phenazepam plus Selank | Examined symptoms and unwanted effects when Selank was added | Cannot separate expectation effects or establish a general combination strategy |
None of these reports is a large placebo-controlled Phase 3 trial. An active comparator can show how two groups changed, but without a placebo group it may be difficult to separate treatment effects from natural improvement, clinical attention and expectations.
The studies also use different diagnoses and designs. Combining their participant counts would not create one larger trial because they did not ask exactly the same question or measure every outcome in the same way.
This evidence is enough to say that Selank has been tested in people. It is not enough to define a dependable effect size, long-term safety or its place relative to established psychological and medical treatments.
What does the immune research show?
The connection with tuftsin led researchers to examine immune signals as well as nervous-system signals.
One human report studied people described as having anxiety-asthenic disorders and measured cytokines before and after a 14-day Selank course. Cytokines are small signalling proteins used by immune cells. The study discussed the balance between two patterns of T-helper-cell signalling, called Th1 and Th2, and reported changes associated with clinical improvement.
The same publication included an experiment on blood cells outside the body. It reported that Selank altered expression of the interleukin-6 gene in cells from selected patients. Interleukin-6, shortened to IL-6, is a cytokine involved in inflammation and many normal immune responses.
These are exploratory findings. Cytokine measurements can vary with infection, stress, sleep, medicines and many other factors. An association between a laboratory measure and symptom change does not show that one caused the other. The study also does not establish Selank as a treatment for an immune condition.
Animal studies have reported changes in inflammation-related genes in spleen tissue. The spleen is an organ involved in filtering blood and coordinating immune responses. These experiments can help identify questions, but a change in a mouse spleen is not evidence of better immunity or fewer infections in people.
Calling Selank an immunomodulator therefore describes an area of research, not an approved or proven immune benefit.
What do cell studies show?
One experiment exposed cultured rat cells to Selank and examined changes in gene expression. Cultured cells are grown under controlled laboratory conditions outside the body. The researchers reported changes in genes connected with neurotransmitter systems and other cell processes.
Cell experiments can help identify possible pathways quickly. They cannot reproduce the brain, immune system, metabolism or lived experience of a person with anxiety. The concentration placed directly onto cells is also not the same as the concentration that reaches human brain tissue after a product is used.
Cell findings should therefore be described as mechanism research, not proof of a clinical benefit.
What do animal studies show?
Researchers have given Selank to mice and rats before behavioural tests intended to model anxiety, learning or stress. Some studies report less avoidance, changes in exploration or altered memory performance.
These tests measure specific behaviours in controlled conditions. They do not show that an animal experiences a human anxiety disorder, nor do they establish better concentration, confidence or wellbeing in people.
Animal studies also allow brain tissue to be collected for chemical and gene analysis. This has supported ideas involving GABA, enkephalins and other signals. The findings are useful for deciding what a human trial might measure, but they cannot replace one.
The models are also highly specific. Some experiments selected animals by their baseline emotional reactivity. Others used prenatal oxygen deprivation, alcohol exposure or genetically defined strains. A result in one model may reveal how Selank behaves under that condition without predicting an effect in a healthy person or someone with a diagnosed disorder.
A 2019 rat study examined memory disruption after alcohol exposure and measured BDNF in the hippocampus and frontal cortex. The hippocampus is important for forming memories, while the frontal cortex supports planning and behavioural control. Selank changed both behaviour and BDNF measurements in that model. The finding does not establish that it protects human memory from alcohol or raises cognition in everyday use.
Another study used WAG/Rij rats, a strain used in research on absence epilepsy and depression-like behaviour. The specialised model adds biological detail but also narrows what can be inferred. No single animal test reproduces the causes, thoughts, physical symptoms and social context of a human anxiety disorder.
Has Selank been studied in healthy people for focus or memory?
The indexed clinical evidence does not provide a large, well-controlled programme in healthy people showing better attention, learning, memory or work performance.
Most cognitive claims trace back to animal tasks, secondary observations in small anxiety studies or changes in genes and signalling proteins. A person whose anxiety improves may also report better concentration because worry is less intrusive. That would not prove a direct cognition-enhancing effect.
A proper healthy-volunteer trial would need a defined population, validated cognitive tests, a credible placebo, masking, advance specification of the main outcome and correction for testing many outcomes. It would also need enough participants to separate a real effect from normal variation and practice effects. A practice effect occurs when someone performs better because they have taken the same test before.
Without that evidence, the word nootropic is a claim category rather than a demonstrated human property.
What did Health Canada's November 2026 peptide contamination warning find?
On 12 November 2026, Health Canada reported that laboratory testing had identified *Sphingomonas aquatilis/melonis* bacteria in an injectable peptide product seized from a retailer in Ottawa. The retailer's unauthorised inventory included products labelled Selank. The agency did not say that every product on its inventory list, or every batch of the named compound, tested positive for bacteria.
This is a product-quality and safety finding, not a new clinical trial of the peptide. Bacterial contamination in material intended for injection can cause serious infection, including sepsis. The agency also warned that a label saying 'for research use only' does not demonstrate sterility or make an unauthorised product suitable for human use. The finding cannot be used to estimate contamination rates across the wider market or to judge the quality of material used in controlled clinical studies.
Is Selank approved?
Russian publications describe Selank as a medicine developed and used in Russia. That national history should not be turned into a claim of international approval.
Selank is not approved by the US Food and Drug Administration, normally called the FDA, or authorised by the European Medicines Agency, normally called the EMA. The FDA regulates medicines in the United States. The EMA evaluates medicines for the European Union.
Regulatory approval applies to a particular finished product, manufacturer, quality standard, medical use and labelling. A vial or nasal product sold online does not inherit regulatory status simply because it carries the Selank name.
FDA separately identifies potential immune reactions associated with aggregation and peptide-related impurities in compounded Selank acetate. Aggregation means peptide molecules clumping together; immunogenicity means the potential to trigger an immune response. FDA also says important human safety information is lacking. This assessment should not be described as an approval or as proof that every possible harm has been demonstrated.
Why is independent replication important for Selank?
Independent replication means that researchers who were not involved in developing a compound repeat a study and obtain a compatible result. It reduces the chance that a finding depends on one laboratory's methods, one clinical setting or selective publication.
Much of the Selank literature comes from a small network of Russian institutes and is published in Russian-language journals with brief English abstracts. This does not make the work invalid. It does mean that outside readers often cannot examine full methods, prespecified outcomes, participant flow or complete adverse-event tables.
Modern medicine-development programmes normally include several phases, registered protocols, larger multicentre trials, independent monitoring and detailed regulatory review. Multicentre means that participants are enrolled at more than one clinic or research site. These features help reveal whether a result holds across different clinicians and populations.
Selank does not have a public international evidence package of that scale. The key missing evidence includes adequately powered placebo-controlled trials, longer follow-up, pharmacokinetic data in humans, interaction studies, reproductive safety information and systematic monitoring for uncommon harms.
This gap is why a plausible mechanism and two small comparative reports cannot support the same confidence as an approved anxiety medicine.
What benefits are claimed, and what does the evidence support?
| Claim | What the evidence supports |
|---|---|
| Reduces anxiety | One small, short clinical comparison reported improvement; larger independent trials are needed |
| Works like a benzodiazepine without sedation | A study reported similar anxiety-score changes with less sedation, but equivalence and long-term safety are not established |
| Improves memory or focus | Mainly animal and laboratory evidence; dependable benefit in healthy people has not been shown |
| Raises BDNF | Reported mainly in animal research; this is not proof of better cognition or mood |
| Regulates the immune system | Selank was derived from tuftsin and affects immune-related signals in experiments, but no approved clinical immune use is established |
| Treats depression | No adequate clinical programme establishes this use |
What is known about side effects?
The available human studies are too small and short to define a complete safety profile. The main clinical paper did not report the sort of detailed adverse-event table found in a modern regulatory assessment.
Claims that Selank does not cause sedation, dependence or withdrawal should be treated carefully. A short study reporting less sedation than a benzodiazepine does not prove the absence of these problems across different people, products and periods of use.
Theoretical risks include unexpected nervous-system effects, allergic reactions and interactions with medicines that affect mood, alertness or GABA signalling. The likelihood and frequency are not known from adequate trials.
Unregulated products create additional risks involving incorrect identity, concentration, purity and microbial contamination. Chemical purity alone does not establish sterility or suitability for human use.
The route used in the small clinical reports creates further uncertainty. Local irritation, altered smell, congestion or other nasal effects would require systematic collection and reporting. The available indexed abstracts do not provide the detailed tables needed to estimate those frequencies.
The absence of a listed adverse event is not evidence that it cannot occur. Small studies are particularly poor at detecting uncommon problems. If a harmful event occurs in one person out of 1,000, a programme involving only dozens of participants can easily miss it.
There is also no adequate evidence package for pregnancy, breastfeeding, children, older adults, liver or kidney impairment. These are not minor omissions. They are standard parts of assessing whether a medicine can be used safely across real populations.
How does Selank compare with Semax?
Selank and Semax are both short synthetic peptides developed through Russian research programmes, but they are different molecules.
Selank is derived from tuftsin and has been studied mainly in anxiety and neuroimmune research. Semax was designed from a fragment of adrenocorticotropic hormone, or ACTH, and has been studied more often in stroke and brain-injury research.
There is no strong direct clinical trial showing that one is better. Laboratory differences do not create a reliable reason to select or combine them. This article does not provide combination advice.
Frequently asked questions
Is Selank a peptide?
Yes. It is a synthetic chain of seven amino acids, known as a heptapeptide.
Is Selank a benzodiazepine?
No. It is a peptide. One small study compared it with the benzodiazepine medazepam, but the compounds have different structures and Selank is not an established substitute.
Does Selank treat anxiety?
A small two-week study reported lower anxiety scores, but larger and independently replicated trials are needed before a dependable treatment effect can be established.
Does Selank improve memory?
Animal and laboratory studies do not establish a meaningful memory benefit in people.
Does Selank affect GABA?
Laboratory studies report changes involving GABA-related signalling and gene activity. The exact human mechanism and clinical importance remain uncertain.
Is Selank approved by the FDA?
No. There is no FDA-approved Selank medicine.
Is Selank approved in Europe?
No Selank medicine is authorised by the European Medicines Agency.
When was Selank developed?
It emerged from Russian short-peptide research in the late twentieth century. English-indexed animal research appeared by 2002 and a main clinical comparison was published in 2008.
How is Selank made?
Research Selank is normally assembled chemically from protected amino-acid building blocks, then separated from incomplete chains and checked for identity and purity.
Is Selank safe?
Its complete short-term and long-term safety profile has not been established in large modern trials.
Can Selank be combined with Semax or anxiety medicines?
This guide provides no stacking or treatment advice. Controlled human evidence has not established the safety or benefit of these combinations.
What the evidence supports today
Selank is a defined seven-amino-acid molecule with a plausible research history and some human evidence. It should not be dismissed as merely a name used by online peptide sellers.
The evidence is still limited. The main clinical comparison was small and brief, detailed modern safety reporting is lacking, and independent international replication is scarce. Much of the evidence for effects on GABA, BDNF, gene activity, memory and stress comes from cells or animals.
The careful description is that Selank is a Russian-developed experimental peptide with preliminary human anxiety research. It is not an FDA-approved or EMA-authorised anxiety medicine, and claims about broad cognitive or emotional benefits go beyond what current clinical evidence can support.
Sources
Research reviewed through 17 November 2026.